Regeneron Pharmaceuticals said Monday it will pay $800 million to Alnylam, a biotechnology firm in Cambridge, Mass., to leverage its gene-silencing technique for the development of new therapies and to become its exclusive partner for new drugs focused on the central nervous system or the eye.
“It’s about the future, and it’s about synergies,” George Yancopoulos, Regeneron’s chief scientific officer and co-founder, said in an interview. “We’re not going to be making the standard deals where companies are just hoping to acquire an asset. We’re going to do the opposite. We’re looking for people with which we can do greater things together.”
About the Author Reprints
